Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects

Aldea, M.Lam, L.Llacer Perez, C.Saint-Ghislain, M.Gravis Mescam, G.Flechon, A.Roubaud, G.Barthelemy, P.Ricci, F.Priou, F.Neviere, Z. M.Beaufils, M.Helissey, C.Ratta, R.Pobel, C.Castro Marcos, E.Thiery-Vuillemin, A.Baciarello, G.Orillard, E.Fizazi, K.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/26936enCabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defectsconference outputopen access10.1016/j.annonc.2020.08.8731569-8041http://www.annalsofoncology.org/article/S0923753420408695/pdf573469100611